Therapeutic targets for neuroendocrine tumors include phosphatidylinositol-3-kinase (PI3K)/Akt and rapamycin (mTOR), both of which are involved in cell-cycle and growth control pathways in cancer (37, 38). Here, MTOR is linked to neuroendocrine neoplasm.